+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Neurodegenerative Drugs Market - Global Forecast 2026-2032- Product Image
Neurodegenerative Drugs Market - Global Forecast 2026-2032- Product Image
Sale

Neurodegenerative Drugs Market - Global Forecast 2026-2032

  • Report

  • 182 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 5888919
UP TO OFF until Dec 31st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Neurodegenerative Drugs Market is projected to reach USD 51.39 Billion in 2026. It is expected to continue growing at a CAGR of 7.92%, reaching USD 81.51 Billion by 2032.

Neurodegenerative drugs address disorders involving progressive neuronal damage, including Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, amyotrophic lateral sclerosis, and related conditions. The field is shaped by high unmet need, complex disease biology, lengthy clinical development, heterogeneous patient populations, and the requirement to demonstrate meaningful functional or cognitive benefit. Therapeutic strategies span disease-modifying approaches, symptomatic treatments, biologics, small molecules, antisense technologies, and supportive-care interventions.

Scientific, Regulatory, and Care-Delivery Shifts Reshaping Development

The landscape is shifting from predominantly symptom management toward earlier intervention and disease modification. Biomarker-based diagnosis, molecular patient stratification, digital monitoring, and adaptive clinical-trial designs are becoming increasingly important for identifying suitable participants and measuring progression. Regulatory expectations are also placing greater emphasis on clinically meaningful endpoints, durability of benefit, safety in older and medically complex populations, and evidence that therapies improve daily functioning or caregiver burden. At the care-delivery level, limited specialist capacity and uneven diagnostic access are encouraging more coordinated models involving primary care, neurology, rehabilitation, pharmacy, and home-based support.

Artificial Intelligence Is Accelerating Discovery, Diagnosis, and Monitoring

Artificial intelligence is influencing neurodegenerative drug development across target identification, compound screening, molecular design, trial recruitment, imaging analysis, and outcome measurement. Machine-learning systems can help detect disease patterns in clinical, imaging, genomic, and longitudinal records, while natural-language tools can improve eligibility screening and evidence synthesis. The greatest cumulative value is likely to come from integrating AI with validated biomarkers and clinical expertise rather than treating algorithmic outputs as standalone evidence. Key constraints include data quality, representativeness, explainability, privacy, cybersecurity, model drift, and the need for prospective validation before AI-supported decisions are used in routine care or regulatory submissions.

Regional Insights: Uneven Access Meets Increasing Research Capability

North America combines advanced research infrastructure, specialist capacity, and strong adoption of biomarker-driven development, but faces affordability, reimbursement, and access challenges. Europe benefits from substantial academic networks and coordinated regulatory and health-technology processes, while national differences in diagnosis, reimbursement, and care pathways remain important. Asia-Pacific is expanding clinical, manufacturing, and translational capabilities, with Japan, China, South Korea, Australia, and India contributing distinct strengths alongside major variation in access. Latin America is prioritizing earlier diagnosis, specialist-network development, and affordable treatment pathways, although infrastructure and reimbursement gaps persist. The Middle East is investing in tertiary care, genomics, and digital health, while Gulf systems generally have stronger infrastructure than neighboring markets. Africa continues to face substantial diagnostic, specialist, supply-chain, and affordability constraints, making scalable care models and capacity building central priorities.

Group Insights: Policy Alignment and Health-System Coordination

ASEAN members present a diverse combination of growing healthcare capacity, varied regulatory maturity, and uneven access to neurology services, creating a strong case for shared standards and regional trial collaboration. BRICS economies offer broad scientific, manufacturing, and patient-base capabilities, but differ significantly in reimbursement, data systems, and clinical infrastructure. The European Union benefits from cross-border scientific collaboration and common regulatory structures, while implementation and access remain shaped by national health systems. G7 countries continue to influence research standards, advanced diagnostics, and evidence generation, yet must address aging populations and rising care burdens. GCC states are strengthening specialist services, genomic programs, and digital infrastructure, with opportunities to coordinate procurement and workforce development. NATO members collectively include substantial biomedical and public-health capabilities, but their health systems and access conditions remain heterogeneous.

Country Insights: Distinct Capabilities and Implementation Priorities

Australia combines strong clinical research with geographically dispersed populations, making telehealth and decentralized care relevant. Brazil and Mexico must balance specialist expansion with affordability and regional access. Canada has advanced research capacity but must address geographic dispersion and provincial variation. China is strengthening translational research, diagnostics, and domestic treatment capabilities, while data governance and access consistency remain important. France, Germany, Italy, and Spain possess established clinical and research systems, with priorities including timely diagnosis, reimbursement sustainability, and coordinated long-term care. India has substantial scientific and pharmaceutical capabilities alongside major variation in specialist access and affordability. Japan faces pronounced aging-related care needs and has strong expertise in neurology, robotics, and digital health. South Korea is advancing biotechnology and digital medicine, while workforce and reimbursement integration remain relevant. Russia’s research and care environment is influenced by infrastructure, supply, and access considerations. The United Kingdom has notable academic and regulatory strengths, with ongoing focus on health-service capacity and equitable adoption. The United States leads in research intensity and specialist infrastructure, while affordability, insurance coverage, trial diversity, and continuity of care remain central challenges.

Actionable Priorities for Neurodegenerative Drug Leaders

Leaders should prioritize disease biology and patient segments where validated biomarkers can improve trial selection and outcome interpretation. Clinical programs should incorporate diverse recruitment, clinically meaningful endpoints, caregiver-relevant outcomes, and long-term safety follow-up from the outset. Organizations should build partnerships with diagnostic providers, health systems, patient groups, and regulators to improve early identification and evidence quality. AI investments should focus on clearly defined use cases, governed data access, independent validation, and human oversight. Commercial and access strategies should account for diagnostic capacity, specialist availability, reimbursement pathways, adherence support, and regional affordability rather than relying on product performance alone. Operational resilience also requires diversified supply chains, scalable manufacturing, pharmacovigilance capability, and workforce development.

Research Methodology: Evidence-Based Synthesis of the Neurodegenerative Drug Landscape

This executive summary uses a structured qualitative synthesis of established scientific, clinical, regulatory, and health-system themes relevant to neurodegenerative drugs. The approach considers therapeutic modalities, disease areas, biomarker development, clinical-trial practices, artificial-intelligence applications, access conditions, and regional health-system characteristics. Regional, group, and country observations are integrated to reflect differences in research capacity, diagnosis, reimbursement, infrastructure, and care delivery. Claims are limited to broadly documented market dynamics and are presented without market estimates, market sizing, market shares, forecasts, or company-specific attribution. Interpretation should be complemented by current primary literature, regulatory publications, clinical guidelines, and jurisdiction-specific reimbursement evidence before investment or policy decisions are made.

Conclusion: Integrating Innovation With Equitable Neurodegenerative Care

The neurodegenerative drugs landscape is progressing toward earlier diagnosis, biologically informed treatment, and more measurable disease modification, but scientific complexity and health-system constraints remain substantial. Success will depend on connecting validated biomarkers, robust clinical evidence, responsible AI, reliable manufacturing, and practical access pathways. Leaders that align innovation with patient and caregiver needs-and tailor implementation to regional and national realities-will be better positioned to translate therapeutic advances into durable improvements in neurological care.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Neurodegenerative Drugs Market, by Drug Type
7.1. Introduction
7.2. Cholinesterase Inhibitors
7.2.1. Donepezil
7.2.2. Pyridostigmine
7.2.3. Rivastigmine
7.3. Decarboxylase Inhibitors
7.3.1. Benserazide
7.3.2. Carbidopa
7.3.3. Methyldopa
7.4. Dopamine Agonist
7.4.1. Apomorphine
7.4.2. Cabergoline
7.4.3. Pramipexole
7.4.4. Rotigotine
7.5. Immunomodulators
8. Neurodegenerative Drugs Market, by Mode Of Administration
8.1. Introduction
8.2. Injectable
8.3. Oral
8.4. Transdermal Patch
9. Neurodegenerative Drugs Market, by Mechanism Of Action
9.1. Introduction
9.2. Ion Channel Modulators
9.2.1. Potassium Channel Modulators
9.2.2. Sodium Channel Modulators
9.3. Synaptic Modulators
10. Neurodegenerative Drugs Market, by Therapeutic Type
10.1. Introduction
10.2. Neuroprotection
10.2.1. Anti-Inflammatory Agents
10.2.2. Antioxidants
10.3. Preventive Treatment
10.4. Symptomatic Treatment
11. Neurodegenerative Drugs Market, by Indication Type
11.1. Introduction
11.2. Alzheimer's Disease
11.3. Amyotrophic Lateral Sclerosis (ALS)
11.4. Multiple Sclerosis
11.4.1. Primary Progressive
11.4.2. Relapsing-Remitting
11.5. Parkinson's Disease
12. Neurodegenerative Drugs Market, by Sales Channel
12.1. Introduction
12.2. Offline
12.2.1. Hospitals Pharmacies
12.2.2. Retail Pharmacies
12.3. Online
13. Neurodegenerative Drugs Market, by End User
13.1. Introduction
13.2. Clinics
13.3. Contract Research Organizations
13.4. Hospitals
13.5. Research Institutes
14. Neurodegenerative Drugs Market, by Region
14.1. Introduction
14.2. Asia-Pacific
14.3. North America
14.4. Latin America
14.5. Europe
14.6. Middle East
14.7. Africa
15. Neurodegenerative Drugs Market, by Group
15.1. Introduction
15.2. ASEAN
15.3. GCC
15.4. European Union
15.5. BRICS
15.6. G7
15.7. NATO
16. Neurodegenerative Drugs Market, by Country
16.1. Introduction
16.2. United States
16.3. Germany
16.4. China
16.5. United Kingdom
16.6. India
16.7. Japan
16.8. Russia
16.9. Brazil
16.10. Canada
16.11. Italy
16.12. Mexico
16.13. France
16.14. Spain
16.15. Australia
16.16. South Korea
17. Competitive Landscape
17.1. Market Share Analysis, 2025
17.2. Market Concentration Analysis, 2025
17.2.1. Concentration Ratio (CR)
17.2.2. Herfindahl Hirschman Index (HHI)
17.3. Recent Developments & Impact Analysis, 2025
17.4. Product Portfolio Analysis, 2025
17.5. Benchmarking Analysis, 2025
18. Company Profiles
18.1. AbbVie Inc
18.2. AC Immune SA
18.3. Acadia Pharmaceuticals Inc
18.4. Alnylam Pharmaceuticals Inc
18.5. Alzheon Inc
18.6. Amneal Pharmaceuticals Inc
18.7. Amylyx Pharmaceuticals Inc
18.8. AstraZeneca PLC
18.9. Bayer AG
18.10. BioArctic AB
18.11. Biogen Inc
18.12. Bristol Myers Squibb Co
18.13. Cassava Sciences Inc
18.14. Denali Therapeutics Inc
18.15. Eisai Co Ltd
18.16. Eli Lilly and Company
18.17. Ionis Pharmaceuticals Inc
18.18. Lundbeck AS
18.19. Merck Co Inc
18.20. Neuren Pharmaceuticals
18.21. Neurocrine Biosciences Inc
18.22. Novartis AG
18.23. Orion Pharma
18.24. Pfizer Inc
18.25. Sage Therapeutics Inc
18.26. Sanofi SA
18.27. Takeda Pharmaceutical Company Limited
18.28. Teva Pharmaceutical Industries Ltd
18.29. UCB SA
18.30. Voyager Therapeutics Inc
19. Key Experts
List of Figures
FIGURE 1. Global Neurodegenerative Drugs Market, Years Considered for the Study
FIGURE 2. Global Neurodegenerative Drugs Market, Research Design
FIGURE 3. Global Neurodegenerative Drugs Market, Research Framework
FIGURE 4. Global Neurodegenerative Drugs Market, Data Triangulation
FIGURE 5. Global Neurodegenerative Drugs Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Neurodegenerative Drugs Market Size, by Drug Type, 2025 vs 2032 (%)
FIGURE 7. Global Neurodegenerative Drugs Market Size, by Drug Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Neurodegenerative Drugs Market Size, by Mode Of Administration, 2025 vs 2032 (%)
FIGURE 9. Global Neurodegenerative Drugs Market Size, by Mode Of Administration, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Neurodegenerative Drugs Market Size, by Mechanism Of Action, 2025 vs 2032 (%)
FIGURE 11. Global Neurodegenerative Drugs Market Size, by Mechanism Of Action, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Neurodegenerative Drugs Market Size, by Therapeutic Type, 2025 vs 2032 (%)
FIGURE 13. Global Neurodegenerative Drugs Market Size, by Therapeutic Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Neurodegenerative Drugs Market Size, by Indication Type, 2025 vs 2032 (%)
FIGURE 15. Global Neurodegenerative Drugs Market Size, by Indication Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Neurodegenerative Drugs Market Size, by Sales Channel, 2025 vs 2032 (%)
FIGURE 17. Global Neurodegenerative Drugs Market Size, by Sales Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Neurodegenerative Drugs Market Size, by End User, 2025 vs 2032 (%)
FIGURE 19. Global Neurodegenerative Drugs Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 20. Global Neurodegenerative Drugs Market Size, by Region, 2025 vs 2032 (%)
FIGURE 21. Global Neurodegenerative Drugs Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 22. Global Neurodegenerative Drugs Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 23. Global Neurodegenerative Drugs Market Size, by Country, 2025 vs 2032 (%)
FIGURE 24. Global Neurodegenerative Drugs Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 25. Global Neurodegenerative Drugs Market Share, by Key Player, 2025
List of Tables
TABLE 1. Global Neurodegenerative Drugs Market Segmentation & Coverage
TABLE 2. Global Neurodegenerative Drugs Market Size, 2017-2032 (USD Million)
TABLE 3. Global Neurodegenerative Drugs Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 4. Global Cholinesterase Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Cholinesterase Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Cholinesterase Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Donepezil Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Donepezil Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Donepezil Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Pyridostigmine Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Pyridostigmine Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Pyridostigmine Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Rivastigmine Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Rivastigmine Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Rivastigmine Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Decarboxylase Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Decarboxylase Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Decarboxylase Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Benserazide Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Benserazide Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Benserazide Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Carbidopa Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global Carbidopa Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global Carbidopa Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global Methyldopa Market Size, by Region, 2017-2032 (USD Million)
TABLE 26. Global Methyldopa Market Size, by Group, 2017-2032 (USD Million)
TABLE 27. Global Methyldopa Market Size, by Country, 2017-2032 (USD Million)
TABLE 28. Global Dopamine Agonist Market Size, by Region, 2017-2032 (USD Million)
TABLE 29. Global Dopamine Agonist Market Size, by Group, 2017-2032 (USD Million)
TABLE 30. Global Dopamine Agonist Market Size, by Country, 2017-2032 (USD Million)
TABLE 31. Global Apomorphine Market Size, by Region, 2017-2032 (USD Million)
TABLE 32. Global Apomorphine Market Size, by Group, 2017-2032 (USD Million)
TABLE 33. Global Apomorphine Market Size, by Country, 2017-2032 (USD Million)
TABLE 34. Global Cabergoline Market Size, by Region, 2017-2032 (USD Million)
TABLE 35. Global Cabergoline Market Size, by Group, 2017-2032 (USD Million)
TABLE 36. Global Cabergoline Market Size, by Country, 2017-2032 (USD Million)
TABLE 37. Global Pramipexole Market Size, by Region, 2017-2032 (USD Million)
TABLE 38. Global Pramipexole Market Size, by Group, 2017-2032 (USD Million)
TABLE 39. Global Pramipexole Market Size, by Country, 2017-2032 (USD Million)
TABLE 40. Global Rotigotine Market Size, by Region, 2017-2032 (USD Million)
TABLE 41. Global Rotigotine Market Size, by Group, 2017-2032 (USD Million)
TABLE 42. Global Rotigotine Market Size, by Country, 2017-2032 (USD Million)
TABLE 43. Global Immunomodulators Market Size, by Region, 2017-2032 (USD Million)
TABLE 44. Global Immunomodulators Market Size, by Group, 2017-2032 (USD Million)
TABLE 45. Global Immunomodulators Market Size, by Country, 2017-2032 (USD Million)
TABLE 46. Global Neurodegenerative Drugs Market Size, by Mode Of Administration, 2017-2032 (USD Million)
TABLE 47. Global Injectable Market Size, by Region, 2017-2032 (USD Million)
TABLE 48. Global Injectable Market Size, by Group, 2017-2032 (USD Million)
TABLE 49. Global Injectable Market Size, by Country, 2017-2032 (USD Million)
TABLE 50. Global Oral Market Size, by Region, 2017-2032 (USD Million)
TABLE 51. Global Oral Market Size, by Group, 2017-2032 (USD Million)
TABLE 52. Global Oral Market Size, by Country, 2017-2032 (USD Million)
TABLE 53. Global Transdermal Patch Market Size, by Region, 2017-2032 (USD Million)
TABLE 54. Global Transdermal Patch Market Size, by Group, 2017-2032 (USD Million)
TABLE 55. Global Transdermal Patch Market Size, by Country, 2017-2032 (USD Million)
TABLE 56. Global Neurodegenerative Drugs Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 57. Global Ion Channel Modulators Market Size, by Region, 2017-2032 (USD Million)
TABLE 58. Global Ion Channel Modulators Market Size, by Group, 2017-2032 (USD Million)
TABLE 59. Global Ion Channel Modulators Market Size, by Country, 2017-2032 (USD Million)
TABLE 60. Global Potassium Channel Modulators Market Size, by Region, 2017-2032 (USD Million)
TABLE 61. Global Potassium Channel Modulators Market Size, by Group, 2017-2032 (USD Million)
TABLE 62. Global Potassium Channel Modulators Market Size, by Country, 2017-2032 (USD Million)
TABLE 63. Global Sodium Channel Modulators Market Size, by Region, 2017-2032 (USD Million)
TABLE 64. Global Sodium Channel Modulators Market Size, by Group, 2017-2032 (USD Million)
TABLE 65. Global Sodium Channel Modulators Market Size, by Country, 2017-2032 (USD Million)
TABLE 66. Global Synaptic Modulators Market Size, by Region, 2017-2032 (USD Million)
TABLE 67. Global Synaptic Modulators Market Size, by Group, 2017-2032 (USD Million)
TABLE 68. Global Synaptic Modulators Market Size, by Country, 2017-2032 (USD Million)
TABLE 69. Global Neurodegenerative Drugs Market Size, by Therapeutic Type, 2017-2032 (USD Million)
TABLE 70. Global Neuroprotection Market Size, by Region, 2017-2032 (USD Million)
TABLE 71. Global Neuroprotection Market Size, by Group, 2017-2032 (USD Million)
TABLE 72. Global Neuroprotection Market Size, by Country, 2017-2032 (USD Million)
TABLE 73. Global Anti-Inflammatory Agents Market Size, by Region, 2017-2032 (USD Million)
TABLE 74. Global Anti-Inflammatory Agents Market Size, by Group, 2017-2032 (USD Million)
TABLE 75. Global Anti-Inflammatory Agents Market Size, by Country, 2017-2032 (USD Million)
TABLE 76. Global Antioxidants Market Size, by Region, 2017-2032 (USD Million)
TABLE 77. Global Antioxidants Market Size, by Group, 2017-2032 (USD Million)
TABLE 78. Global Antioxidants Market Size, by Country, 2017-2032 (USD Million)
TABLE 79. Global Preventive Treatment Market Size, by Region, 2017-2032 (USD Million)
TABLE 80. Global Preventive Treatment Market Size, by Group, 2017-2032 (USD Million)
TABLE 81. Global Preventive Treatment Market Size, by Country, 2017-2032 (USD Million)
TABLE 82. Global Symptomatic Treatment Market Size, by Region, 2017-2032 (USD Million)
TABLE 83. Global Symptomatic Treatment Market Size, by Group, 2017-2032 (USD Million)
TABLE 84. Global Symptomatic Treatment Market Size, by Country, 2017-2032 (USD Million)
TABLE 85. Global Neurodegenerative Drugs Market Size, by Indication Type, 2017-2032 (USD Million)
TABLE 86. Global Alzheimer's Disease Market Size, by Region, 2017-2032 (USD Million)
TABLE 87. Global Alzheimer's Disease Market Size, by Group, 2017-2032 (USD Million)
TABLE 88. Global Alzheimer's Disease Market Size, by Country, 2017-2032 (USD Million)
TABLE 89. Global Amyotrophic Lateral Sclerosis (ALS) Market Size, by Region, 2017-2032 (USD Million)
TABLE 90. Global Amyotrophic Lateral Sclerosis (ALS) Market Size, by Group, 2017-2032 (USD Million)
TABLE 91. Global Amyotrophic Lateral Sclerosis (ALS) Market Size, by Country, 2017-2032 (USD Million)
TABLE 92. Global Multiple Sclerosis Market Size, by Region, 2017-2032 (USD Million)
TABLE 93. Global Multiple Sclerosis Market Size, by Group, 2017-2032 (USD Million)
TABLE 94. Global Multiple Sclerosis Market Size, by Country, 2017-2032 (USD Million)
TABLE 95. Global Primary Progressive Market Size, by Region, 2017-2032 (USD Million)
TABLE 96. Global Primary Progressive Market Size, by Group, 2017-2032 (USD Million)
TABLE 97. Global Primary Progressive Market Size, by Country, 2017-2032 (USD Million)
TABLE 98. Global Relapsing-Remitting Market Size, by Region, 2017-2032 (USD Million)
TABLE 99. Global Relapsing-Remitting Market Size, by Group, 2017-2032 (USD Million)
TABLE 100. Global Relapsing-Remitting Market Size, by Country, 2017-2032 (USD Million)
TABLE 101. Global Parkinson's Disease Market Size, by Region, 2017-2032 (USD Million)
TABLE 102. Global Parkinson's Disease Market Size, by Group, 2017-2032 (USD Million)
TABLE 103. Global Parkinson's Disease Market Size, by Country, 2017-2032 (USD Million)
TABLE 104. Global Neurodegenerative Drugs Market Size, by Sales Channel, 2017-2032 (USD Million)
TABLE 105. Global Offline Market Size, by Region, 2017-2032 (USD Million)
TABLE 106. Global Offline Market Size, by Group, 2017-2032 (USD Million)
TABLE 107. Global Offline Market Size, by Country, 2017-2032 (USD Million)
TABLE 108. Global Hospitals Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 109. Global Hospitals Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 110. Global Hospitals Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 111. Global Retail Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 112. Global Retail Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 113. Global Retail Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 114. Global Online Market Size, by Region, 2017-2032 (USD Million)
TABLE 115. Global Online Market Size, by Group, 2017-2032 (USD Million)
TABLE 116. Global Online Market Size, by Country, 2017-2032 (USD Million)
TABLE 117. Global Neurodegenerative Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 118. Global Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 119. Global Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 120. Global Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 121. Global Contract Research Organizations Market Size, by Region, 2017-2032 (USD Million)
TABLE 122. Global Contract Research Organizations Market Size, by Group, 2017-2032 (USD Million)
TABLE 123. Global Contract Research Organizations Market Size, by Country, 2017-2032 (USD Million)
TABLE 124. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 125. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 126. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 127. Global Research Institutes Market Size, by Region, 2017-2032 (USD Million)
TABLE 128. Global Research Institutes Market Size, by Group, 2017-2032 (USD Million)
TABLE 129. Global Research Institutes Market Size, by Country, 2017-2032 (USD Million)
TABLE 130. Global Neurodegenerative Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 131. Asia-Pacific Neurodegenerative Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 132. Asia-Pacific Neurodegenerative Drugs Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 133. Asia-Pacific Neurodegenerative Drugs Market Size, by Cholinesterase Inhibitors, 2017-2032 (USD Million)
TABLE 134. Asia-Pacific Neurodegenerative Drugs Market Size, by Decarboxylase Inhibitors, 2017-2032 (USD Million)
TABLE 135. Asia-Pacific Neurodegenerative Drugs Market Size, by Dopamine Agonist, 2017-2032 (USD Million)
TABLE 136. Asia-Pacific Neurodegenerative Drugs Market Size, by Mode Of Administration, 2017-2032 (USD Million)
TABLE 137. Asia-Pacific Neurodegenerative Drugs Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 138. Asia-Pacific Neurodegenerative Drugs Market Size, by Ion Channel Modulators, 2017-2032 (USD Million)
TABLE 139. Asia-Pacific Neurodegenerative Drugs Market Size, by Therapeutic Type, 2017-2032 (USD Million)
TABLE 140. Asia-Pacific Neurodegenerative Drugs Market Size, by Neuroprotection, 2017-2032 (USD Million)
TABLE 141. Asia-Pacific Neurodegenerative Drugs Market Size, by Indication Type, 2017-2032 (USD Million)
TABLE 142. Asia-Pacific Neurodegenerative Drugs Market Size, by Multiple Sclerosis, 2017-2032 (USD Million)
TABLE 143. Asia-Pacific Neurodegenerative Drugs Market Size, by Sales Channel, 2017-2032 (USD Million)
TABLE 144. Asia-Pacific Neurodegenerative Drugs Market Size, by Offline, 2017-2032 (USD Million)
TABLE 145. Asia-Pacific Neurodegenerative Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 146. North America Neurodegenerative Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 147. North America Neurodegenerative Drugs Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 148. North America Neurodegenerative Drugs Market Size, by Cholinesterase Inhibitors, 2017-2032 (USD Million)
TABLE 149. North America Neurodegenerative Drugs Market Size, by Decarboxylase Inhibitors, 2017-2032 (USD Million)
TABLE 150. North America Neurodegenerative Drugs Market Size, by Dopamine Agonist, 2017-2032 (USD Million)
TABLE 151. North America Neurodegenerative Drugs Market Size, by Mode Of Administration, 2017-2032 (USD Million)
TABLE 152. North America Neurodegenerative Drugs Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 153. North America Neurodegenerative Drugs Market Size, by Ion Channel Modulators, 2017-2032 (USD Million)
TABLE 154. North America Neurodegenerative Drugs Market Size, by Therapeutic Type, 2017-2032 (USD Million)
TABLE 155. North America Neurodegenerative Drugs Market Size, by Neuroprotection, 2017-2032 (USD Million)
TABLE 156. North America Neurodegenerative Drugs Market Size, by Indication Type, 2017-2032 (USD Million)
TABLE 157. North America Neurodegenerative Drugs Market Size, by Multiple Sclerosis, 2017-2032 (USD Million)
TABLE 158. North America Neurodegenerative Drugs Market Size, by Sales Channel, 2017-2032 (USD Million)
TABLE 159. North America Neurodegenerative Drugs Market Size, by Offline, 2017-2032 (USD Million)
TABLE 160. North America Neurodegenerative Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 161. Latin America Neurodegenerative Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 162. Latin America Neurodegenerative Drugs Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 163. Latin America Neurodegenerative Drugs Market Size, by Cholinesterase Inhibitors, 2017-2032 (USD Million)
TABLE 164. Latin America Neurodegenerative Drugs Market Size, by Decarboxylase Inhibitors, 2017-2032 (USD Million)
TABLE 165. Latin America Neurodegenerative Drugs Market Size, by Dopamine Agonist, 2017-2032 (USD Million)
TABLE 166. Latin America Neurodegenerative Drugs Market Size, by Mode Of Administration, 2017-2032 (USD Million)
TABLE 167. Latin America Neurodegenerative Drugs Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 168. Latin America Neurodegenerative Drugs Market Size, by Ion Channel Modulators, 2017-2032 (USD Million)
TABLE 169. Latin America Neurodegenerative Drugs Market Size, by Therapeutic Type, 2017-2032 (USD Million)
TABLE 170. Latin America Neurodegenerative Drugs Market Size, by Neuroprotection, 2017-2032 (USD Million)
TABLE 171. Latin America Neurodegenerative Drugs Market Size, by Indication Type, 2017-2032 (USD Million)
TABLE 172. Latin America Neurodegenerative Drugs Market Size, by Multiple Sclerosis, 2017-2032 (USD Million)
TABLE 173. Latin America Neurodegenerative Drugs Market Size, by Sales Channel, 2017-2032 (USD Million)
TABLE 174. Latin America Neurodegenerative Drugs Market Size, by Offline, 2017-2032 (USD Million)
TABLE 175. Latin America Neurodegenerative Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 176. Europe Neurodegenerative Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 177. Europe Neurodegenerative Drugs Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 178. Europe Neurodegenerative Drugs Market Size, by Cholinesterase Inhibitors, 2017-2032 (USD Million)
TABLE 179. Europe Neurodegenerative Drugs Market Size, by Decarboxylase Inhibitors, 2017-2032 (USD Million)
TABLE 180. Europe Neurodegenerative Drugs Market Size, by Dopamine Agonist, 2017-2032 (USD Million)
TABLE 181. Europe Neurodegenerative Drugs Market Size, by Mode Of Administration, 2017-2032 (USD Million)
TABLE 182. Europe Neurodegenerative Drugs Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 183. Europe Neurodegenerative Drugs Market Size, by Ion Channel Modulators, 2017-2032 (USD Million)
TABLE 184. Europe Neurodegenerative Drugs Market Size, by Therapeutic Type, 2017-2032 (USD Million)
TABLE 185. Europe Neurodegenerative Drugs Market Size, by Neuroprotection, 2017-2032 (USD Million)
TABLE 186. Europe Neurodegenerative Drugs Market Size, by Indication Type, 2017-2032 (USD Million)
TABLE 187. Europe Neurodegenerative Drugs Market Size, by Multiple Sclerosis, 2017-2032 (USD Million)
TABLE 188. Europe Neurodegenerative Drugs Market Size, by Sales Channel, 2017-2032 (USD Million)
TABLE 189. Europe Neurodegenerative Drugs Market Size, by Offline, 2017-2032 (USD Million)
TABLE 190. Europe Neurodegenerative Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 191. Middle East Neurodegenerative Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 192. Middle East Neurodegenerative Drugs Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 193. Middle East Neurodegenerative Drugs Market Size, by Cholinesterase Inhibitors, 2017-2032 (USD Million)
TABLE 194. Middle East Neurodegenerative Drugs Market Size, by Decarboxylase Inhibitors, 2017-2032 (USD Million)
TABLE 195. Middle East Neurodegenerative Drugs Market Size, by Dopamine Agonist, 2017-2032 (USD Million)
TABLE 196. Middle East Neurodegenerative Drugs Market Size, by Mode Of Administration, 2017-2032 (USD Million)
TABLE 197. Middle East Neurodegenerative Drugs Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 198. Middle East Neurodegenerative Drugs Market Size, by Ion Channel Modulators, 2017-2032 (USD Million)
TABLE 199. Middle East Neurodegenerative Drugs Market Size, by Therapeutic Type, 2017-2032 (USD Million)
TABLE 200. Middle East Neurodegenerative Drugs Market Size, by Neuroprotection, 2017-2032 (USD Million)
TABLE 201. Middle East Neurodegenerative Drugs Market Size, by Indication Type, 2017-2032 (USD Million)
TABLE 202. Middle East Neurodegenerative Drugs Market Size, by Multiple Sclerosis, 2017-2032 (USD Million)
TABLE 203. Middle East Neurodegenerative Drugs Market Size, by Sales Channel, 2017-2032 (USD Million)
TABLE 204. Middle East Neurodegenerative Drugs Market Size, by Offline, 2017-2032 (USD Million)
TABLE 205. Middle East Neurodegenerative Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 206. Africa Neurodegenerative Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 207. Africa Neurodegenerative Drugs Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 208. Africa Neurodegenerative Drugs Market Size, by Cholinesterase Inhibitors, 2017-2032 (USD Million)
TABLE 209. Africa Neurodegenerative Drugs Market Size, by Decarboxylase Inhibitors, 2017-2032 (USD Million)
TABLE 210. Africa Neurodegenerative Drugs Market Size, by Dopamine Agonist, 2017-2032 (USD Million)
TABLE 211. Africa Neurodegenerative Drugs Market Size, by Mode Of Administration, 2017-2032 (USD Million)
TABLE 212. Africa Neurodegenerative Drugs Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 213. Africa Neurodegenerative Drugs Market Size, by Ion Channel Modulators, 2017-2032 (USD Million)
TABLE 214. Africa Neurodegenerative Drugs Market Size, by Therapeutic Type, 2017-2032 (USD Million)
TABLE 215. Africa Neurodegenerative Drugs Market Size, by Neuroprotection, 2017-2032 (USD Million)
TABLE 216. Africa Neurodegenerative Drugs Market Size, by Indication Type, 2017-2032 (USD Million)
TABLE 217. Africa Neurodegenerative Drugs Market Size, by Multiple Sclerosis, 2017-2032 (USD Million)
TABLE 218. Africa Neurodegenerative Drugs Market Size, by Sales Channel, 2017-2032 (USD Million)
TABLE 219. Africa Neurodegenerative Drugs Market Size, by Offline, 2017-2032 (USD Million)
TABLE 220. Africa Neurodegenerative Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 221. Global Neurodegenerative Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 222. ASEAN Neurodegenerative Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 223. ASEAN Neurodegenerative Drugs Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 224. ASEAN Neurodegenerative Drugs Market Size, by Cholinesterase Inhibitors, 2017-2032 (USD Million)
TABLE 225. ASEAN Neurodegenerative Drugs Market Size, by Decarboxylase Inhibitors, 2017-2032 (USD Million)
TABLE 226. ASEAN Neurodegenerative Drugs Market Size, by Dopamine Agonist, 2017-2032 (USD Million)
TABLE 227. ASEAN Neurodegenerative Drugs Market Size, by Mode Of Administration, 2017-2032 (USD Million)
TABLE 228. ASEAN Neurodegenerative Drugs Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 229. ASEAN Neurodegenerative Drugs Market Size, by Ion Channel Modulators, 2017-2032 (USD Million)
TABLE 230. ASEAN Neurodegenerative Drugs Market Size, by Therapeutic Type, 2017-2032 (USD Million)
TABLE 231. ASEAN Neurodegenerative Drugs Market Size, by Neuroprotection, 2017-2032 (USD Million)
TABLE 232. ASEAN Neurodegenerative Drugs Market Size, by Indication Type, 2017-2032 (USD Million)
TABLE 233. ASEAN Neurodegenerative Drugs Market Size, by Multiple Sclerosis, 2017-2032 (USD Million)
TABLE 234. ASEAN Neurodegenerative Drugs Market Size, by Sales Channel, 2017-2032 (USD Million)
TABLE 235. ASEAN Neurodegenerative Drugs Market Size, by Offline, 2017-2032 (USD Million)
TABLE 236. ASEAN Neurodegenerative Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 237. GCC Neurodegenerative Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 238. GCC Neurodegenerative Drugs Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 239. GCC Neurodegenerative Drugs Market Size, by Cholinesterase Inhibitors, 2017-2032 (USD Million)
TABLE 240. GCC Neurodegenerative Drugs Market Size, by Decarboxylase Inhibitors, 2017-2032 (USD Million)
TABLE 241. GCC Neurodegenerative Drugs Market Size, by Dopamine Agonist, 2017-2032 (USD Million)
TABLE 242. GCC Neurodegenerative Drugs Market Size, by Mode Of Administration, 2017-2032 (USD Million)
TABLE 243. GCC Neurodegenerative Drugs Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 244. GCC Neurodegenerative Drugs Market Size, by Ion Channel Modulators, 2017-2032 (USD Million)
TABLE 245. GCC Neurodegenerative Drugs Market Size, by Therapeutic Type, 2017-2032 (USD Million)
TABLE 246. GCC Neurodegenerative Drugs Market Size, by Neuroprotection, 2017-2032 (USD Million)
TABLE 247. GCC Neurodegenerative Drugs Market Size, by Indication Type, 2017-2032 (USD Million)
TABLE 248. GCC Neurodegenerative Drugs Market Size, by Multiple Sclerosis, 2017-2032 (USD Million)
TABLE 249. GCC Neurodegenerative Drugs Market Size, by Sales Channel, 2017-2032 (USD Million)
TABLE 250. GCC Neurodegenerative Drugs Market Size, by Offline, 2017-2032 (USD Million)
TABLE 251. GCC Neurodegenerative Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 252. European Union Neurodegenerative Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 253. European Union Neurodegenerative Drugs Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 254. European Union Neurodegenerative Drugs Market Size, by Cholinesterase Inhibitors, 2017-2032 (USD Million)
TABLE 255. European Union Neurodegenerative Drugs Market Size, by Decarboxylase Inhibitors, 2017-2032 (USD Million)
TABLE 256. European Union Neurodegenerative Drugs Market Size, by Dopamine Agonist, 2017-2032 (USD Million)
TABLE 257. European Union Neurodegenerative Drugs Market Size, by Mode Of Administration, 2017-2032 (USD Million)
TABLE 258. European Union Neurodegenerative Drugs Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 259. European Union Neurodegenerative Drugs Market Size, by Ion Channel Modulators, 2017-2032 (USD Million)
TABLE 260. European Union Neurodegenerative Drugs Market Size, by Therapeutic Type, 2017-2032 (USD Million)
TABLE 261. European Union Neurodegenerative Drugs Market Size, by Neuroprotection, 2017-2032 (USD Million)
TABLE 262. European Union Neurodegenerative Drugs Market Size, by Indication Type, 2017-2032 (USD Million)
TABLE 263. European Union Neurodegenerative Drugs Market Size, by Multiple Sclerosis, 2017-2032 (USD Million)
TABLE 264. European Union Neurodegenerative Drugs Market Size, by Sales Channel, 2017-2032 (USD Million)
TABLE 265. European Union Neurodegenerative Drugs Market Size, by Offline, 2017-2032 (USD Million)
TABLE 266. European Union Neurodegenerative Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 267. BRICS Neurodegenerative Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 268. BRICS Neurodegenerative Drugs Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 269. BRICS Neurodegenerative Drugs Market Size, by Cholinesterase Inhibitors, 2017-2032 (USD Million)
TABLE 270. BRICS Neurodegenerative Drugs Market Size, by Decarboxylase Inhibitors, 2017-2032 (USD Million)
TABLE 271. BRICS Neurodegenerative Drugs Market Size, by Dopamine Agonist, 2017-2032 (USD Million)
TABLE 272. BRICS Neurodegenerative Drugs Market Size, by Mode Of Administration, 2017-2032 (USD Million)
TABLE 273. BRICS Neurodegenerative Drugs Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 274. BRICS Neurodegenerative Drugs Market Size, by Ion Channel Modulators, 2017-2032 (USD Million)
TABLE 275. BRICS Neurodegenerative Drugs Market Size, by Therapeutic Type, 2017-2032 (USD Million)
TABLE 276. BRICS Neurodegenerative Drugs Market Size, by Neuroprotection, 2017-2032 (USD Million)
TABLE 277. BRICS Neurodegenerative Drugs Market Size, by Indication Type, 2017-2032 (USD Million)
TABLE 278. BRICS Neurodegenerative Drugs Market Size, by Multiple Sclerosis, 2017-2032 (USD Million)
TABLE 279. BRICS Neurodegenerative Drugs Market Size, by Sales Channel, 2017-2032 (USD Million)
TABLE 280. BRICS Neurodegenerative Drugs Market Size, by Offline, 2017-2032 (USD Million)
TABLE 281. BRICS Neurodegenerative Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 282. G7 Neurodegenerative Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 283. G7 Neurodegenerative Drugs Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 284. G7 Neurodegenerative Drugs Market Size, by Cholinesterase Inhibitors, 2017-2032 (USD Million)
TABLE 285. G7 Neurodegenerative Drugs Market Size, by Decarboxylase Inhibitors, 2017-2032 (USD Million)
TABLE 286. G7 Neurodegenerative Drugs Market Size, by Dopamine Agonist, 2017-2032 (USD Million)
TABLE 287. G7 Neurodegenerative Drugs Market Size, by Mode Of Administration, 2017-2032 (USD Million)
TABLE 288. G7 Neurodegenerative Drugs Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 289. G7 Neurodegenerative Drugs Market Size, by Ion Channel Modulators, 2017-2032 (USD Million)
TABLE 290. G7 Neurodegenerative Drugs Market Size, by Therapeutic Type, 2017-2032 (USD Million)
TABLE 291. G7 Neurodegenerative Drugs Market Size, by Neuroprotection, 2017-2032 (USD Million)
TABLE 292. G7 Neurodegenerative Drugs Market Size, by Indication Type, 2017-2032 (USD Million)
TABLE 293. G7 Neurodegenerative Drugs Market Size, by Multiple Sclerosis, 2017-2032 (USD Million)
TABLE 294. G7 Neurodegenerative Drugs Market Size, by Sales Channel, 2017-2032 (USD Million)
TABLE 295. G7 Neurodegenerative Drugs Market Size, by Offline, 2017-2032 (USD Million)
TABLE 296. G7 Neurodegenerative Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 297. NATO Neurodegenerative Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 298. NATO Neurodegenerative Drugs Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 299. NATO Neurodegenerative Drugs Market Size, by Cholinesterase Inhibitors, 2017-2032 (USD Million)
TABLE 300. NATO Neurodegenerative Drugs Market Size, by Decarboxylase Inhibitors, 2017-2032 (USD Million)
TABLE 301. NATO Neurodegenerative Drugs Market Size, by Dopamine Agonist, 2017-2032 (USD Million)
TABLE 302. NATO Neurodegenerative Drugs Market Size, by Mode Of Administration, 2017-2032 (USD Million)
TABLE 303. NATO Neurodegenerative Drugs Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 304. NATO Neurodegenerative Drugs Market Size, by Ion Channel Modulators, 2017-2032 (USD Million)
TABLE 305. NATO Neurodegenerative Drugs Market Size, by Therapeutic Type, 2017-2032 (USD Million)
TABLE 306. NATO Neurodegenerative Drugs Market Size, by Neuroprotection, 2017-2032 (USD Million)
TABLE 307. NATO Neurodegenerative Drugs Market Size, by Indication Type, 2017-2032 (USD Million)
TABLE 308. NATO Neurodegenerative Drugs Market Size, by Multiple Sclerosis, 2017-2032 (USD Million)
TABLE 309. NATO Neurodegenerative Drugs Market Size, by Sales Channel, 2017-2032 (USD Million)
TABLE 310. NATO Neurodegenerative Drugs Market Size, by Offline, 2017-2032 (USD Million)
TABLE 311. NATO Neurodegenerative Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 312. Global Neurodegenerative Drugs Market Size, by Country, 2017-2032 (USD Million)
TABLE 313. United States Neurodegenerative Drugs Market Size, 2017-2032 (USD Million)
TABLE 314. United States Neurodegenerative Drugs Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 315. United States Neurodegenerative Drugs Market Size, by Cholinesterase Inhibitors, 2017-2032 (USD Million)
TABLE 316. United States Neurodegenerative Drugs Market Size, by Decarboxylase Inhibitors, 2017-2032 (USD Million)
TABLE 317. United States Neurodegenerative Drugs Market Size, by Dopamine Agonist, 2017-2032 (USD Million)
TABLE 318. United States Neurodegenerative Drugs Market Size, by Mode Of Administration, 2017-2032 (USD Million)
TABLE 319. United States Neurodegenerative Drugs Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 320. United States Neurodegenerative Drugs Market Size, by Ion Channel Modulators, 2017-2032 (USD Million)
TABLE 321. United States Neurodegenerative Drugs Market Size, by Therapeutic Type, 2017-2032 (USD Million)
TABLE 322. United States Neurodegenerative Drugs Market Size, by Neuroprotection, 2017-2032 (USD Million)
TABLE 323. United States Neurodegenerative Drugs Market Size, by Indication Type, 2017-2032 (USD Million)
TABLE 324. United States Neurodegenerative Drugs Market Size, by Multiple Sclerosis, 2017-2032 (USD Million)
TABLE 325. United States Neurodegenerative Drugs Market Size, by Sales Channel, 2017-2032 (USD Million)
TABLE 326. United States Neurodegenerative Drugs Market Size, by Offline, 2017-2032 (USD Million)
TABLE 327. United States Neurodegenerative Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 328. Germany Neurodegenerative Drugs Market Size, 2017-2032 (USD Million)
TABLE 329. Germany Neurodegenerative Drugs Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 330. Germany Neurodegenerative Drugs Market Size, by Cholinesterase Inhibitors, 2017-2032 (USD Million)
TABLE 331. Germany Neurodegenerative Drugs Market Size, by Decarboxylase Inhibitors, 2017-2032 (USD Million)
TABLE 332. Germany Neurodegenerative Drugs Market Size, by Dopamine Agonist, 2017-2032 (USD Million)
TABLE 333. Germany Neurodegenerative Drugs Market Size, by Mode Of Administration, 2017-2032 (USD Million)
TABLE 334. Germany Neurodegenerative Drugs Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 335. Germany Neurodegenerative Drugs Market Size, by Ion Channel Modulators, 2017-2032 (USD Million)
TABLE 336. Germany Neurodegenerative Drugs Market Size, by Therapeutic Type, 2017-2032 (USD Million)
TABLE 337. Germany Neurodegenerative Drugs Market Size, by Neuroprotection, 2017-2032 (USD Million)
TABLE 338. Germany Neurodegenerative Drugs Market Size, by Indication Type, 2017-2032 (USD Million)
TABLE 339. Germany Neurodegenerative Drugs Market Size, by Multiple Sclerosis, 2017-2032 (USD Million)
TABLE 340. Germany Neurodegenerative Drugs Market Size, by Sales Channel, 2017-2032 (USD Million)
TABLE 341. Germany Neurodegenerative Drugs Market Size, by Offline, 2017-2032 (USD Million)
TABLE 342. Germany Neurodegenerative Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 343. China Neurodegenerative Drugs Market Size, 2017-2032 (USD Million)
TABLE 344. China Neurodegenerative Drugs Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 345. China Neurodegenerative Drugs Market Size, by Cholinesterase Inhibitors, 2017-2032 (USD Million)
TABLE 346. China Neurodegenerative Drugs Market Size, by Decarboxylase Inhibitors, 2017-2032 (USD Million)
TABLE 347. China Neurodegenerat

Companies Mentioned

  • AbbVie Inc
  • AC Immune SA
  • Acadia Pharmaceuticals Inc
  • Alnylam Pharmaceuticals Inc
  • Alzheon Inc
  • Amneal Pharmaceuticals Inc
  • Amylyx Pharmaceuticals Inc
  • AstraZeneca PLC
  • Bayer AG
  • BioArctic AB
  • Biogen Inc
  • Bristol Myers Squibb Co
  • Cassava Sciences Inc
  • Denali Therapeutics Inc
  • Eisai Co Ltd
  • Eli Lilly and Company
  • Ionis Pharmaceuticals Inc
  • Lundbeck AS
  • Merck Co Inc
  • Neuren Pharmaceuticals
  • Neurocrine Biosciences Inc
  • Novartis AG
  • Orion Pharma
  • Pfizer Inc
  • Sage Therapeutics Inc
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd
  • UCB SA
  • Voyager Therapeutics Inc

Table Information

Report AttributeDetails
No. of Pages182
PublishedSeptember 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 51.39 Billion
Forecasted Market Value ( USD ) by 2032 $ 81.51 Billion
Compound Annual Growth Rate7.9%
Regions CoveredGlobal
No. of Companies Mentioned30

Related Topics

Related Reports

Neurodegenerative Diseases Therapeutics - Global Strategic Business Report - Product Image

Neurodegenerative Diseases Therapeutics - Global Strategic Business Report

  • Report
  • 387 Pages
  • Global
From
Neurodegenerative Drugs Market - Global Strategic Business Report - Product Image

Neurodegenerative Drugs Market - Global Strategic Business Report

  • Report
  • 376 Pages
  • Global
From
Neurodegenerative Diseases Market - Global Forecast 2025-2032 - Product Image

Neurodegenerative Diseases Market - Global Forecast 2025-2032

  • Report
  • 183 Pages
  • Global
From
Neurodegenerative Disease - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

Neurodegenerative Disease - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 120 Pages
  • Global
From
Neurodegenerative Disorder Therapeutics Market Report 2026 - Product Image

Neurodegenerative Disorder Therapeutics Market Report 2026

  • Report
  • 250 Pages
  • Global
From

About the Neurodegenerative Disease Drug Market

The Neurodegenerative Disease Drug market is a subset of the Central Nervous System Drugs market, which focuses on treatments for diseases that cause the progressive loss of structure or function of neurons, including Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis (ALS). These drugs are typically used to slow the progression of the disease, improve symptoms, and improve quality of life. Common treatments include cholinesterase inhibitors, glutamate antagonists, and dopamine agonists. The Neurodegenerative Disease Drug market is highly competitive, with many large pharmaceutical companies vying for market share. Some of the major players in the market include Pfizer, Novartis, Merck, Sanofi, and Johnson & Johnson. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.